Therapeutic or Preventive Procedure
Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)
agentic AI; breast cancer treatment; oncology; clinical decision support; multi-agent systems; healthcare workflow automation; personalized medicine; AWS HealthLake; Microsoft Teams integration; AI-guided treatment planning
Recent Advances in AI & Multi-Omics for Translational Research
AI-driven multi-omics integration; translational research; precision medicine; biomarker discovery; patient stratification; machine learning; foundation models; agentic AI; cancer research; drug response prediction
Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026
Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine
Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment
GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence
ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy
ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology
GSK and LTZ Therapeutics Announce $50M Partnership to Develop First-in-Class Myeloid Cell Engagers for Cancer
GSK; LTZ Therapeutics; myeloid cell engagers; oncology; hematologic cancers; solid tumors; immunotherapy; strategic collaboration; biotechnology; $50 million upfront; preclinical programs
US-Backed Group Reports Success with New Tuberculosis Treatment in Phase 2 Study
tuberculosis; TB Alliance; Phase 2 clinical trial; sorfequiline; SPaL regimen; pretomanid; linezolid; drug-resistant TB; ultra-short regimen; US support; clinical trial results
Spotlight On: Big Pharma’s Big Bets on In Vivo Cell Therapy
in vivo cell therapy; CAR-T; acquisition; autoimmune disease; gene therapy; manufacturing; scalability; Bristol Myers Squibb; Gilead; AbbVie; AstraZeneca
Roche’s Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial
Roche; oral SERD; giredestrant; Phase 3 trial; early breast cancer; ER-positive; HER2-negative; disease-free survival; adjuvant therapy; recurrence prevention
Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study
Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation